SCHEMBL4471152

SCHEMBL4471152

CCOC(=O)C1CCC(=O)CC1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 1/20 0.47
TLR4 O00206 1/20 0.47
RECQL P46063 1/20 0.42
ALOX12 P18054 1/20 0.41
CYP2D6 P10635 1/20 0.36
RAB9A P51151 1/20 0.36
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1134463 0.85 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL7127925 0.82 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL28395084 0.80 ALDH1A1 (0.36) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL321283 0.79 TLR4 (0.52) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL12606807 0.79 TLR4 (0.52) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL2470785 0.77 TLR4 (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL276016 0.77 TLR4 (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E
Ethylene SCHEMBL10579767 0.76 TLR4 (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL7733726 0.76 TLR4 (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL7392059 0.76 TLR4 (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727923-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258904-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
US-10941500-B1 Method and system for diamond electrodeposition MYRICK JAMES J (US) 2021-03-09 US disclosed
US-9977024-B2 Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-22 US disclosed
US-20160195532-A1 Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines THE SCRIPPS RESEARCH INSTITUTE 2016-07-07 US disclosed
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed
US-7351720-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-01 US disclosed
US-7351720-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-01 US disclosed
US-7291744-B2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-06 US disclosed
US-7291744-B2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-06 US disclosed
US-20040259914-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA CD47, SLC11A2, G6PD ALDH1A1 873/4885MEN1 2318/4885KMT2A 2203/4885
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ACKR3, CCR7, CCR2 ALDH1A1 914/4885MEN1 4524/4885KMT2A 4445/4885
US-20040259914-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity ACKR3, CCR1, CXCR1 ALDH1A1 671/4885MEN1 4286/4885KMT2A 4523/4885
US-20160195532-A1 Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines PTMS, RSU1, QSOX1 ALDH1A1 3255/4885MEN1 4819/4885KMT2A 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.